Weekly Digests

2026

September

Breaking down the mechanism of enfortumab vedotin

September 9, 2026

Enfortumab vedotin (marketed under the brand name Padcev) is an approved antibody–drug conjugate (ADC) that targets Nectin-4 on cancer cells and delivers a payload of microtubule-disrupting monomethyl auristatin E (MMAE) to tumor cells. In recent work, Olson and Liu et al. thoroughly investigated the mechanism of action of enfortumab vedotin, and identified direct...

Aire-ing out a tumor’s dirty laundry: manipulating tumoral AIRE to boost antitumor immunity

September 2, 2026

The autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTECs) is essential for the negative selection of autoreactive T cells in the thymus by inducing expression of peripheral tissue-specific antigens. Chen, Pulido, et al. hypothesized that AIRE expression in cancer cells may mimic this thymic process by establishing a “selfness” profile...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.